Zebrafish: a new model on the pharmaceutical catwalk.
Zebrafish is recognized as one of the most important vertebrate model organisms; however, its value in pharmacological studies has not been extensively explored and exploited. In this review, I summarize significant findings about the effects of drugs and medicines on important physiological processes in zebrafish. Our experiments have shown that cardiovascular, anti-angiogenic and anti-cancer drugs elicit comparable responses in zebrafish embryos to those in mammalian systems. Similar observations have been reported by other laboratories, exposing zebrafish to a variety of pharmaceutical active compounds affecting a range of different processes. All the data summarized indicate that zebrafish represents a very valuable organism for different kinds of pharmacological studies, such as screenings of chemical libraries, lead validation and optimization, mode-of-action studies, analysis of gene function, predictive toxicology and teratogenicity, pharmacogenomics and toxicogenomics. Zebrafish pharmacological assays have specific advantages compared to in vitro cell culture studies and in vivo experiments using mice, complementing these assays to give valuable guides for future tests of new drugs for human therapy.
Langheinrich
Ulrike
U
Exelixis Deutschland GmbH, Spemannstrasse 35, D-72076 Tübingen, Germany. U.Langheinrich@exelixis-de.com
D000818:Animals; D017209:Apoptosis; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D004345:Drug Industry; D006321:Heart / Q000502:physiology; D006487:Hemostasis; D006801:Humans; D007249:Inflammation; D050356:Lipid Metabolism; D023421:Models, Animal; D009389:Neovascularization, Pathologic; D015027:Zebrafish / Q000235:genetics* / Q000502:physiology*